하이드록시 프로게스테론 카프로에이트 주사제 시장 보고서 : 동향, 예측 및 경쟁 분석(-2031년)
Hydroxyprogesterone Caproate Injection Market Report: Trends, Forecast and Competitive Analysis to 2031
상품코드:1881995
리서치사:Lucintel
발행일:2025년 12월
페이지 정보:영문 150 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계 하이드록시프로게스테론 카프론산 주사제 시장은 조산 예방 및 호르몬 대체 요법 시장에서의 기회를 배경으로 미래가 유망할 것으로 예측됩니다. 세계 하이드록시프로게스테론 카프론산 주사제 시장은 2025-2031년 연평균 복합 성장률(CAGR) 6.2%를 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 조산 사례 증가, 모성 건강 요법에 대한 수요 증가, 산전 관리 솔루션에 대한 관심 확대 등입니다.
Lucintel의 예측에 따르면, 제품 유형별로는 다회용 바이알이 예측 기간 동안 더 높은 성장률을 보일 것으로 예측됩니다.
용도별로는 조산 예방 분야가 더 높은 성장률을 보일 것으로 예측됩니다.
지역별로는 북미가 예측 기간 동안 가장 높은 성장률을 보일 것으로 예측됩니다.
하이드록시프로게스테론 카프론산 주사제 시장의 새로운 트렌드
현재 하이드록시프로게스테론 카프론산 주사제 시장은 임상적 유효성에 대한 재평가로 인해 큰 불확실성과 위축의 시기를 맞이하고 있습니다. 새로운 트렌드는 성장보다는 이 약물로부터의 근본적인 전환에 초점을 맞추고 있으며, 조산 예방을 위한 보다 효과적인 대안적 개입 방법을 모색하는 데 초점을 맞추었습니다.
대체 프로게스테론제로의 전환: 가장 두드러진 추세는 하이드록시프로게스테론카프론산에서 대체 프로게스테론제, 특히 천연 프로게스테론으로 전환하는 것입니다. 의료진은 최근 임상적 유효성 증거와 우수한 안전성 프로파일을 바탕으로 질 내 투여 또는 경구용 프로게스테론을 대안으로 처방하는 경우가 증가하고 있으며, 이는 시장을 변화시키고 있습니다.
프로게스테론 연구에 대한 관심 증가: 하이드록시프로게스테론카프론산에 대한 규제 조치로 인해 임신 중 프로게스테론의 역할에 대한 연구가 증가하는 추세를 주도하고 있습니다. 과학자들은 현재 조산에 대한 진정으로 효과적이고 안전한 치료법을 찾기 위해 프로게스테론의 작용기전과 최적의 투여 방법을 밝히는 데 집중하고 있습니다.
개인 맞춤형 의료의 발전: 조산 예방에 있어 개인 맞춤형 의료로의 전환이 새로운 트렌드로 떠오르고 있습니다. 획일적인 접근법 대신 자궁경부 길이 등 환자 개개인의 위험요인을 파악하는 데 중점을 두어 단일 약물에 대한 의존도를 넘어 보다 타겟팅된 효과적인 개입이 가능해졌습니다.
임상시험 데이터의 재평가: 중요한 동향으로 과거 임상시험 데이터의 재평가를 들 수 있습니다. 하이드록시프로게스테론 카프론산의 효능을 확인하는 시험이 실패하면서 산부인과 영역에서 보다 엄격하고 적절하게 설계된 연구의 필요성이 부각되었습니다. 이를 통해 향후 의약품 승인 기준과 의학적 근거의 수준을 높이고 있습니다.
비약물 요법에 대한 관심 증가: 하이드록시프로게스테론카프론산이 직면한 도전은 비약물 요법에 대한 재조명이라는 추세를 촉진하고 있습니다. 여기에는 생활습관 개선, 임산부의 영양 상태 개선, 통합적 케어 모델 등이 포함됩니다. 이 전환은 임산부의 건강과 복지에 대한 종합적인 접근을 강조하는 것입니다.
하이드록시프로게스테론카프론산 시장의 새로운 추세는 성장 추세가 아니라 오히려 축소 추세입니다. 그 비효율성과 잠재적 위험성을 강조하는 규제 조치와 과학적 발견으로 인해 시장은 재편되고 있으며, 보다 안전하고 효과적인 대안으로 근본적인 전환과 모성 건강 조사의 새로운 시대로 나아가고 있습니다.
하이드록시프로게스테론 카프론산 주사제 시장의 최근 동향
하이드록시프로게스테론 카프론산 주사제 시장은 이 약물의 수년간의 사용에 의문을 제기하는 규제 조치에 의해 크게 정의되는 최근 중요한 추세를 경험했습니다. 이러한 추세는 주요 시장에서 약품의 철수로 이어져 조산 예방 치료 전략의 재평가를 요구하고 있습니다.
미국 FDA의 마케나 승인 취소: 미국 식품의약국(FDA)이 2023년 마케나(상품명: 하이드록시프로게스테론카프론산주사제)의 승인을 취소하기로 결정한 것은 획기적인 진전입니다. 이번 조치는 임상적 유효성을 입증하지 못한 확인시험 결과를 반영한 것입니다. 이로써 이 약품은 사실상 미국 시장에서 철수하게 되었습니다.
유럽 EMA의 판매중지 권고: 이와 동시에 유럽의약품청(EMA)은 유럽연합(EU) 전역에서 이 약의 판매 승인 중단을 권고했습니다. 조산 예방 효과의 부족과 자손의 암 위험 가능성(미확인이지만 우려되는)을 이유로 들었으며, 이 조치는 FDA의 입장을 반영하는 것으로 유럽 시장 철수로 이어지고 있습니다.
기존 데이터에 대한 엄격한 검증: 이러한 규제 조치에 따라, 이 약의 사용을 뒷받침하는 임상 데이터에 대한 전 세계적인 재평가가 진행되고 있습니다. 이로 인해 과거 연구에 대한 검증이 강화되고, 결과의 불일치 및 양성 결과의 재현성 부족이 밝혀져 이 약의 효능에 대한 신뢰가 떨어지고 있습니다.
배합제제에 대한 관심: 브랜드 제품의 철수에 따라 하이드록시프로게스테론 카프론산 배합제제에 대한 관심이 높아지고 있습니다. 이들 제제는 FDA 승인을 받지 못했지만 일부 의료진들이 계속 사용하고 있어 틈새 시장을 형성하고 있습니다. 규제 당국의 견해에도 불구하고 이 약품에 대한 수요가 지속되고 있음을 보여주고 있습니다.
제네릭 대체품의 성장: 이전 시장에서는 마케나의 제네릭 도입으로 경쟁이 심화되고 가격이 하락하는 움직임을 보였습니다. 그러나 FDA가 브랜드 의약품의 승인을 취소함에 따라 이들 제네릭 승인도 철회되면서 이 성장 궤도는 사실상 멈춰버렸습니다.
최근 하이드록시프로게스테론 카프론산 주사제 시장 동향은 세계 주요 시장에서의 철수를 중심으로 압도적으로 부정적으로 나타나고 있습니다. 이러한 움직임은 조산 예방의 치료 패러다임에 근본적인 변화를 가져오고 있으며, 의료계는 보다 효과적이고 안전한 대체 요법의 탐색과 검증을 서둘러야 할 필요성에 직면해 있습니다.
목차
제1장 주요 요약
제2장 시장 개요
배경과 분류
공급망
제3장 시장 동향과 예측 분석
업계 촉진요인과 과제
PESTLE 분석
특허 분석
규제 환경
제4장 세계의 하이드록시 프로게스테론 카프로에이트 주사제 시장 : 제품 유형별
매력 분석 : 제품 유형별
단회 투여 바이알
다회 투여 바이알
제5장 세계의 하이드록시 프로게스테론 카프로에이트 주사제 시장 : 유통 채널별
매력 분석 : 유통 채널별
병원 약국
소매 약국
온라인 약국
제6장 세계의 하이드록시 프로게스테론 카프로에이트 주사제 시장 : 용도별
매력 분석 : 용도별
조산 예방
호르몬 대체요법
기타
제7장 지역 분석
제8장 북미의 하이드록시 프로게스테론 카프로에이트 주사제 시장
북미 하이드록시 프로게스테론 카프로에이트 주사제 시장 : 유형별
북미 하이드록시 프로게스테론 카프로에이트 주사제 시장 : 용도별
미국 하이드록시 프로게스테론 카프로에이트 주사제 시장
멕시코 하이드록시 프로게스테론 카프로에이트 주사제 시장
캐나다 하이드록시 프로게스테론 카프로에이트 주사제 시장
제9장 유럽의 하이드록시 프로게스테론 카프로에이트 주사제 시장
유럽 하이드록시 프로게스테론 카프로에이트 주사제 시장 : 유형별
유럽 하이드록시 프로게스테론 카프로에이트 주사제 시장 : 용도별
독일 하이드록시 프로게스테론 카프로에이트 주사제 시장
프랑스 하이드록시 프로게스테론 카프로에이트 주사제 시장
스페인 하이드록시 프로게스테론 카프로에이트 주사제 시장
이탈리아 하이드록시 프로게스테론 카프로에이트 주사제 시장
영국 하이드록시 프로게스테론 카프로에이트 주사제 시장
제10장 아시아태평양의 하이드록시 프로게스테론 카프로에이트 주사제 시장
아시아태평양 하이드록시 프로게스테론 카프로에이트 주사제 시장 : 유형별
아시아태평양 하이드록시 프로게스테론 카프로에이트 주사제 시장 : 용도별
일본 하이드록시 프로게스테론 카프로에이트 주사제 시장
인도 하이드록시 프로게스테론 카프로에이트 주사제 시장
중국 하이드록시 프로게스테론 카프로에이트 주사제 시장
한국 하이드록시 프로게스테론 카프로에이트 주사제 시장
인도네시아 하이드록시 프로게스테론 카프로에이트 주사제 시장
제11장 기타 지역(ROW)의 하이드록시 프로게스테론 카프로에이트 주사제 시장
ROW 하이드록시 프로게스테론 카프로에이트 주사제 시장 : 유형별
ROW 하이드록시 프로게스테론 카프로에이트 주사제 시장 : 용도별
중동 하이드록시 프로게스테론 카프로에이트 주사제 시장
남미 하이드록시 프로게스테론 카프로에이트 주사제 시장
아프리카 하이드록시 프로게스테론 카프로에이트 주사제 시장
제12장 경쟁 분석
제품 포트폴리오 분석
운영 통합
Porter의 Five Forces 분석
시장 점유율 분석
제13장 기회와 전략 분석
밸류체인 분석
성장 기회 분석
세계 하이드록시 프로게스테론 카프로에이트 주사제 시장의 새로운 동향
전략 분석
제14장 밸류체인 주요 기업 개요
경쟁 분석
AMAG Pharmaceuticals
McGuff Pharmaceuticals
Aspen Oss
American Regent
Bayer
Teva Pharmaceutical Industries
Mylan
Pfizer
Sanofi
Merck & Co.
제15장 부록
LSH
영문 목차
영문목차
The future of the global hydroxyprogesterone caproate injection market looks promising with opportunities in the preterm birth prevention and hormone replacement therapy markets. The global hydroxyprogesterone caproate injection market is expected to grow with a CAGR of 6.2% from 2025 to 2031. The major drivers for this market are the increasing number of preterm birth cases, the rising demand for maternal health therapies, and the growing focus on prenatal care solutions.
Lucintel forecasts that, within the product type category, multi-dose vial is expected to witness higher growth over the forecast period.
Within the application category, preterm birth prevention is expected to witness higher growth.
In terms of region, North America is expected to witness the highest growth over the forecast period.
Emerging Trends in the Hydroxyprogesterone Caproate Injection Market
The hydroxyprogesterone caproate injection market is currently experiencing a period of significant uncertainty and contraction due to a re-evaluation of its clinical efficacy. Emerging trends are not focused on growth but rather on a fundamental shift away from this drug, highlighting a search for alternative and more effective interventions for preterm birth prevention.
Shift to Alternative Progestogens: The most significant trend is the shift away from hydroxyprogesterone caproate and toward alternative progestogens, particularly natural progesterone. Healthcare providers are increasingly prescribing vaginal or oral progesterone as a substitute, backed by more recent clinical evidence of efficacy and a better safety profile, thereby transforming the market.
Increased Focus on Progesterone Research: The regulatory actions against hydroxyprogesterone caproate have fueled a trend toward increased research into progesterone's role in pregnancy. Scientists are now focusing on understanding the mechanisms of action and optimal delivery methods of progesterone to find a truly effective and safe treatment for preterm birth.
Growth in Personalized Medicine: An emerging trend is the move toward personalized medicine in preterm birth prevention. Instead of a one-size-fits-all approach, a growing focus on identifying individual patient risk factors, such as cervical length, is leading to more targeted and effective interventions that move beyond a reliance on a single drug.
Re-evaluation of Clinical Trial Data: A key trend is the re-evaluation of historical clinical trial data. The failure of a confirmatory trial to prove the efficacy of hydroxyprogesterone caproate has highlighted the need for more rigorous, well-designed studies in obstetrics. This is raising the bar for future drug approvals and the standards of medical evidence.
Focus on Non-Pharmacological Interventions: The challenges facing hydroxyprogesterone caproate are driving a trend toward a renewed focus on non-pharmacological interventions. This includes lifestyle changes, improved maternal nutrition, and integrated care models. This shift emphasizes a holistic approach to maternal health and well-being.
The emerging trends in the hydroxyprogesterone caproate market are not trends of growth, but rather of dissolution. The market is being reshaped by regulatory actions and scientific findings that have highlighted its inefficacy and potential risks, leading to a fundamental shift toward safer and more effective alternatives and a new era of research in maternal health.
Recent Developments in the Hydroxyprogesterone Caproate Injection Market
The hydroxyprogesterone caproate injection market has experienced profound recent developments, largely defined by regulatory actions that have challenged the drug's long-standing use. These developments have led to the withdrawal of the drug from key markets, compelling a re-evaluation of treatment strategies for preventing preterm birth.
FDA Withdrawal of Makena: A landmark development was the U.S. FDA's decision to withdraw the approval of Makena, the branded hydroxyprogesterone caproate injection, in 2023. This action followed a confirmatory trial that failed to show a clinical benefit. This development has effectively eliminated the drug from the U.S. market.
European EMA Suspension: In a parallel development, the European Medicines Agency (EMA) recommended the suspension of the drug's marketing authorizations across the EU. Citing a lack of efficacy in preventing preterm birth and an unconfirmed but possible risk of cancer in offspring, this action mirrors the FDA's stance and is leading to its withdrawal from European markets.
Heightened Scrutiny of Existing Data: These regulatory actions have prompted a global re-evaluation of the clinical data supporting the drug's use. This has created a heightened level of scrutiny on historical studies, revealing inconsistencies and a failure to replicate positive results, which has eroded confidence in the drug's effectiveness.
Focus on Compounded Alternatives: In response to the withdrawal of the branded product, a development has been the increased focus on compounded versions of hydroxyprogesterone caproate. While these formulations are not FDA-approved, some practitioners have continued to use them, creating a niche market and highlighting a continued demand for the drug despite regulatory findings.
Growth of Generic Alternatives: The market had previously seen a development with the introduction of generic versions of Makena, which increased competition and lowered prices. However, with the FDA's withdrawal of approval for the branded drug, these generic approvals were also rescinded, effectively halting this growth trajectory.
The recent developments in the hydroxyprogesterone caproate injection market have been overwhelmingly negative, centered on its withdrawal from major global markets. These developments are forcing a fundamental change in the treatment paradigm for preterm birth prevention, pushing the medical community to seek out and validate more effective and safer alternatives.
Strategic Growth Opportunities in the Hydroxyprogesterone Caproate Injection Market
Given the significant regulatory setbacks, strategic growth opportunities in the hydroxyprogesterone caproate injection market are limited and highly challenging. Any opportunities that exist are not in expansion but rather in a re-evaluation of its niche applications and a potential re-entry to the market with new, verifiable evidence.
Re-evaluation in Niche Indications: A strategic opportunity could involve a re-evaluation of hydroxyprogesterone caproate's use in highly specific, niche indications where it may still show some efficacy. This could involve small, targeted clinical trials to validate its use in specific patient subgroups or for other gynecological conditions beyond preterm birth prevention.
Development of New Formulations: A potential growth opportunity could be the development of a new formulation or delivery system with a better safety profile and proven efficacy. This would require a significant investment in R&D and a new clinical trial program to meet stringent regulatory requirements, offering a pathway for a product to re-enter the market.
Focus on Emerging Markets: While major markets are withdrawing the drug, a strategic opportunity might exist in emerging markets where regulatory standards and access to alternatives may differ. Companies could focus on gaining approvals in these regions, provided they can demonstrate a favorable risk-benefit profile to local authorities.
Partnerships for Re-research: Another opportunity lies in forming strategic partnerships with academic institutions and research organizations to conduct new, large-scale, well-designed clinical trials. This is crucial for gathering the robust evidence needed to either re-establish the drug's efficacy or definitively prove its lack thereof.
Market for Compounded Formulations: While highly controversial, a growth opportunity currently exists in the compounded pharmacy market. Companies could strategically focus on providing high-quality active pharmaceutical ingredients (APIs) to compounding pharmacies, catering to the remaining demand for this product in the absence of a branded version.
The strategic growth opportunities in the hydroxyprogesterone caproate market are not for business as usual. They are high-risk, high-investment endeavors focused on rebuilding a market that has been largely dismantled by regulatory bodies. Any future success would require a complete paradigm shift and the generation of new, compelling clinical evidence.
Hydroxyprogesterone Caproate Injection Market Driver and Challenges
The hydroxyprogesterone caproate injection market is characterized by a unique set of drivers and challenges. The market's previous growth was driven by a high demand for preterm birth prevention and initial clinical findings. However, its recent decline is overwhelmingly influenced by new, contradictory evidence and stringent regulatory actions.
The factors responsible for driving the hydroxyprogesterone caproate injection market include:
1. High Preterm Birth Rates: The primary historical driver was the high global incidence of preterm birth, a leading cause of infant morbidity and mortality. This created a significant and urgent medical need for an effective prophylactic treatment, which hydroxyprogesterone caproate was initially believed to be.
2. Initial Favorable Clinical Data: The market was initially driven by the positive results from a 2003 clinical trial (Meis Trial) that suggested the drug was effective in preventing recurrent preterm birth. This trial provided the foundation for the drug's initial accelerated approval and widespread adoption.
3. Orphan Drug Designation: The drug's orphan drug status in the U.S. provided significant market exclusivity and incentives for its development. This protected the branded product from immediate generic competition and drove investment, allowing it to become a major player in maternal health.
4. Perceived Lack of Alternatives: For a period, hydroxyprogesterone caproate was viewed as the only FDA-approved treatment for its specific indication, which was a strong market driver. The perceived lack of effective alternatives for high-risk women fueled its widespread use.
5. Physician Recommendation: The endorsement by major medical societies and organizations, based on the initial clinical data, was a significant driver. This helped solidify its position as a standard of care and encouraged obstetricians to prescribe the drug to eligible patients.
Challenges in the hydroxyprogesterone caproate injection market are:
1. Failure to Confirm Efficacy: The most significant challenge is the failure of a large, confirmatory clinical trial (PROLONG study) to prove the drug's efficacy. This finding directly contradicted the initial data, leading to a loss of confidence and the ultimate withdrawal of the product.
2. Regulatory Actions and Withdrawal: The U.S. FDA's and European EMA's decisions to withdraw or suspend the drug's marketing authorizations are insurmountable challenges. These regulatory actions are effectively eliminating the product from major global markets, making it difficult for it to be prescribed or sold.
3. Potential Safety Concerns: The unconfirmed but possible link to an increased risk of cancer in offspring exposed to the drug in utero is a major challenge. This safety concern, cited by the EMA, further undermines its benefit-risk profile and makes its use highly controversial.
The hydroxyprogesterone caproate market's trajectory has been a cautionary tale. While once driven by a clear medical need and promising initial data, it has been decimated by the failure to confirm its efficacy and the subsequent regulatory actions. The challenges are now far greater than the initial drivers, making the market's future highly uncertain.
List of Hydroxyprogesterone Caproate Injection Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies hydroxyprogesterone caproate injection companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the hydroxyprogesterone caproate injection companies profiled in this report include-
AMAG Pharmaceuticals
McGuff Pharmaceuticals
Aspen Oss
American Regent
Bayer
Teva Pharmaceutical Industries
Mylan
Pfizer
Sanofi
Merck & Co.
Hydroxyprogesterone Caproate Injection Market by Segment
The study includes a forecast for the global hydroxyprogesterone caproate injection market by product type, distribution channel, application, and region.
Hydroxyprogesterone Caproate Injection Market by Product Type [Value from 2019 to 2031]:
Single-Dose Vials
Multi-Dose Vials
Hydroxyprogesterone Caproate Injection Market by Distribution Channel [Value from 2019 to 2031]:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Hydroxyprogesterone Caproate Injection Market by Application [Value from 2019 to 2031]:
Preterm Birth Prevention
Hormone Replacement Therapy
Others
Country Wise Outlook for the Hydroxyprogesterone Caproate Injection Market
The hydroxyprogesterone caproate injection market is facing significant global challenges and a period of re-evaluation. Recent developments are primarily centered around regulatory actions and a re-assessment of the drug's efficacy and safety profile. These shifts are challenging its long-standing position as a primary therapy for preventing preterm birth.
United States: The U.S. market has undergone a dramatic change. Following a review that failed to confirm its clinical benefit, the FDA withdrew its approval for the branded drug Makena and its generics in 2023. This has led to the complete removal of the product from the market, fundamentally reshaping the landscape for preterm birth prevention.
China: The market in China is at an early stage, with limited data available on the use of hydroxyprogesterone caproate injections. While preterm birth prevention is a medical priority, the market is not as developed as in other regions. There is a need for further research and clinical data to establish the drug's role in the country's healthcare system.
Germany: In Germany, and across the EU, the European Medicines Agency (EMA) has recommended the suspension of marketing authorizations for hydroxyprogesterone caproate-containing medicines. This decision, based on a lack of efficacy and a possible but unconfirmed cancer risk in offspring, is prompting a withdrawal of the drug from the market.
India: The Indian market is currently small and not a primary focus for this treatment. However, as preterm birth rates are a significant public health issue, there is a potential for future growth. The market is driven by increasing awareness and improving healthcare infrastructure, but the drug's recent regulatory setbacks may impact its future in India.
Japan: Japan's market is characterized by a cautious approach to new and existing drugs. The use of hydroxyprogesterone caproate injections is limited. The drug's recent regulatory setbacks in the U.S. and Europe are likely to influence Japan's regulatory bodies and medical community, leading to a potential re-evaluation of its use.
Features of the Global Hydroxyprogesterone Caproate Injection Market
Market Size Estimates: Hydroxyprogesterone caproate injection market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Hydroxyprogesterone caproate injection market size by product type, distribution channel, application, and region in terms of value ($B).
Regional Analysis: Hydroxyprogesterone caproate injection market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different product types, distribution channels, applications, and regions for the hydroxyprogesterone caproate injection market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the hydroxyprogesterone caproate injection market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the hydroxyprogesterone caproate injection market by product type (single-dose vials and multi-dose vials), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), application (preterm birth prevention, hormone replacement therapy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Table of Contents
1. Executive Summary
2. Market Overview
2.1 Background and Classifications
2.2 Supply Chain
3. Market Trends & Forecast Analysis
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment
4. Global Hydroxyprogesterone Caproate Injection Market by Product Type
4.1 Overview
4.2 Attractiveness Analysis by Product Type
4.3 Single-Dose Vials: Trends and Forecast (2019-2031)
4.4 Multi-Dose Vials: Trends and Forecast (2019-2031)
5. Global Hydroxyprogesterone Caproate Injection Market by Distribution Channel
5.1 Overview
5.2 Attractiveness Analysis by Distribution Channel
5.3 Hospital Pharmacies: Trends and Forecast (2019-2031)
5.4 Retail Pharmacies: Trends and Forecast (2019-2031)
5.5 Online Pharmacies: Trends and Forecast (2019-2031)
6. Global Hydroxyprogesterone Caproate Injection Market by Application
6.1 Overview
6.2 Attractiveness Analysis by Application
6.3 Preterm Birth Prevention: Trends and Forecast (2019-2031)
6.4 Hormone Replacement Therapy: Trends and Forecast (2019-2031)
6.5 Others: Trends and Forecast (2019-2031)
7. Regional Analysis
7.1 Overview
7.2 Global Hydroxyprogesterone Caproate Injection Market by Region
8. North American Hydroxyprogesterone Caproate Injection Market
8.1 Overview
8.2 North American Hydroxyprogesterone Caproate Injection Market by Product Type
8.3 North American Hydroxyprogesterone Caproate Injection Market by Application
8.4 United States Hydroxyprogesterone Caproate Injection Market
